Lincocin TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: lincomycin
Pack: Lincocin 600 mg/2 mL injection, 5 x 2 mL vials
Brand name
(ARTG)
: LINCOCIN lincomycin 600 mg/2 mL (as hydrochloride) injection vialDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
INDICATIONS AS AT 22 SEPTEMBER 1994: LINCOCIN is indicated in the treatment of serious infections due to susceptible strains of gram positive aerobes such as streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. Because of the risk of colitis (see PRECAUTIONS), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g.erythromycin). LINCOCIN has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. Staphylococcal strains resistant to LINCOCIN have been recovered; culture and susceptibility studies should be done in conjunction with LINCOCIN therapy. In the case of macrolides, partial but not complete cross resistance may occur. The drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see PRECAUTIONS). The specific infections for which LINCOCIN is indicated are as follows: - Upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. Effectiveness in the treatment of mastoiditis would be anticipated. - Lower respiratory infections including acute and chronic bronchitis and pneumonia. - Skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. Conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy. - Bone and joint infections including osteomyelitis and septic arthritis. - Septicaemia and endocarditis. Selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. However, bactericidal drugs are often preferred for these infections. - Bacillary Dysentery. Although Shigella is resistant to lincomycin in vitro (MIC approximately 200-400 micrograms/mL), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000-7000 micrograms/gram of stool).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Injection, solution
- Intravenous
- Clear colourless liquid
Storage conditions
(ARTG)
- Store below 25 degrees Celsius
- Protect from Light
- Do not Freeze
- Shelf lifetime is 2 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 5 X 2mL pack
Is this medicine subsidised ?
(PBS)
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on December, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient lincomycin
This medicine is generally considered safe during pregnancy if taken as directed. During pregnancy, you should discuss your medicine use with your doctor or pharmacist.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems